SUPPLEMENT SCIENCEInsights
Search

Search Insights

Try choline, nano-curcumin or probiotics.

    Botanical guide · Ingredient reference

    Long-term ashwagandha use: three months of data cannot establish indefinite safety

    Short-term tolerability does not answer the risks of continuous use over years. Evidence also does not validate a standard cycling schedule that makes prolonged use safe.

    Read the evidence ↓

    Supplement Science Insights Editorial Team

    Published September 23, 2026

    The observation window limits the conclusion

    ODS describes ashwagandha as generally well tolerated in studies lasting up to about three months, while noting that longer-term safety is not established. Common reported effects include stomach upset, loose stools, nausea and drowsiness. Liver and thyroid concerns also matter. [1]

    A small study may be too short or too small to identify uncommon harms. Participants who tolerate a preparation for several weeks do not establish that everyone can use it indefinitely, particularly when a retail extract differs from the one studied. [1]

    A break is not a validated risk-control schedule

    The reviewed evidence does not identify a standard number of days on and off that prevents liver injury, thyroid effects or interactions. An invented cycling schedule cannot repair a missing long-term study. [1]

    Duration belongs in a periodic review alongside the reason for use, actual benefit, adverse effects and changes in medicines or health. The relevant question is whether continued use still has a defensible benefit–risk balance, not simply whether a calendar reminder has been followed. [1]

    Separate observed time from intended time

    Imagine an extract was studied for eight weeks but a buyer plans to take it for two years. The trial covers only a small part of the proposed exposure period. Calling the longer course established safe would add evidence the study did not collect.

    Hypothetical example — an exposure gap
    ObservationInterpretation
    Eight-week trialObserved duration
    Two-year planMuch longer exposure
    Scheduled breaksNot proof of long-term safety
    Long-term ashwagandha use: three months of data cannot establish indefinite safety — original article outline diagram
    Original editorial diagram of this article’s sections; no product photograph or clinical finding is depicted.

    Sources for this article

    1. NIH ODS: Ashwagandha — Health Professional Fact Sheet
      Source consulted: 2026-09-17. This is a reference resource, not a claim that we conducted the studies or tested a product.